Intraocular Drug Delivery Systems for Diabetic Retinopathy

Novel drug delivery systems constitute a substantial advancement in pharmaceutical research and development, designed to optimize the efficacy of therapeutic agents via innovative delivery modalities. The primary purpose of these systems is the targeted delivery of therapeutic compounds to specific anatomical sites, such as tumors and affected tissues, with the dual objective of attenuating adverse effects and toxicity associated with the drugs while simultaneously amplifying therapeutic efficacy. New ways of delivering drugs are being studied to make them work better. These new methods aim to get the medicine to the exact place where it needs to go, like tumors or sick tissues. This helps to reduce side effects and make the medicine stronger. Numerous innovative drug delivery strategies have been investigated for their potential application in targeted ocular drug delivery. A variety of novel carriers, including implants, hydrogels, metal nanoparticles, nanoliposomes, micelles, solid lipid nanoparticles, emulsions, and biodegradable nanoparticles, have been employed to facilitate the controlled release of pharmaceutical agents to the retina and vitreous. These carriers offer distinct advantages such as enhanced intraocular drug delivery, precise control over drug release kinetics, increased stability, and superior entrapment efficiency. This comprehensive review aims to elucidate the current advancements in carriers and their contemporary applications in the treatment of diabetic retinopathy.